X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with HER2-Positive Breast Cancer.
Lead Product(s): BDC-1001,Pertuzumab
Therapeutic Area: Oncology Product Name: BDC-1001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid tumors.
Lead Product(s): BDC-3042,Pembrolizumab
Therapeutic Area: Oncology Product Name: BDC-3042
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
Lead Product(s): BDC-1001,Nivolumab
Therapeutic Area: Oncology Product Name: BDC-1001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist, in development forHER2-positive colorectal, endometrial and gastroesophageal cancers.
Lead Product(s): BDC-1001,Nivolumab
Therapeutic Area: Oncology Product Name: BDC-1001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
Under the agreement, Roche will provide pertuzumab in support of a Phase 2 metastatic breast cancer trial to evaluate pertuzumab in combination with BDC-1001.
Lead Product(s): BDC-1001,Pertuzumab
Therapeutic Area: Oncology Product Name: BDC-1001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 29, 2023
Details:
BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with HER2-expressing cancer.
Lead Product(s): BDC-1001,Nivolumab
Therapeutic Area: Oncology Product Name: BDC-1001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Bolt is developing a pipeline of myeloid-targeting therapies, including BDC-1001, immune-stimulating antibody conjugates (ISACs) and BDC-3042 (a Dectin-2 agonistic antibody), designed to kill tumors through activation of myeloid cells and subsequent recruitment of T cells.
Lead Product(s): BDC-1001,Nivolumab
Therapeutic Area: Oncology Product Name: BDC-1001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
Three of Bolt Biotherapeutics’ preclinical programs will be featured in presentation: (1) BDC-2034, a CEA-targeting immune-stimulating antibody conjugate (2) BDC-3042, a Dectin-2-targeting, myeloid-modulating antibody, and (3) a PD-L1-targeting ISAC.
Lead Product(s): BDC-2034
Therapeutic Area: Oncology Product Name: BDC-2034
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Initial safety and early efficacy findings reported from the ongoing monotherapy arm of the Phase 1/2 clinical trial make BDC-1001 (Trastuzumab-TLR7/8 conjugate) a potentially promising candidate for the treatment of patients with HER2 in combination with OPDIVO.
Lead Product(s): Trastuzumab-TLR7/8 conjugate,Nivolumab
Therapeutic Area: Oncology Product Name: BDC-1001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
Details:
BDC-1001 (Trastuzumab-TLR7/8 conjugate), is an immune-stimulating antibody conjugate comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to an innovative TLR7/8 agonist.
Lead Product(s): Trastuzumab-TLR7/8 conjugate,Nivolumab
Therapeutic Area: Oncology Product Name: BDC-1001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
